Orthofix Projects 2026 Net Sales Between $825M and $830M Following Q3 Results
Orthofix Medical (OFIX) reported third-quarter results that fell below management's initial expectations. Despite the miss, CEO Massimo Calafiore noted underlying strength in specific business segments, including limb reconstruction, therapeutic solutions, and a stabilizing trend within the U.S. biologics market. Looking ahead, the company has provided long-term guidance, anticipating net sales in the range of $825 million to $830 million for 2026. This projection is supported by what management describes as accelerated actions within their U.S. spine business segment.
Tickers: $OFIX
Topics: biologics earnings results limb reconstruction quarterly performance therapeutic solutions
Read the full article at Seeking Alpha
Part of the story P3 Health Reports Q3 2026 Profitability Turnaround and Increased Full-Year Guidance (7 articles)